Myriad Genetics (MYGN) Q1 2026 earnings review
Mental Health Surges, But Prenatal Weakness Drags Profitability into the Red
Myriad's Q1 2026 results expose a stark divergence across its portfolio. Total revenue grew a Stable 2% to $200.4M, directly meeting the soft expectations set last quarter. The Mental Health (GeneSight) segment surged 24% YoY, fully recovering from last year's severe payer headwinds. However, Prenatal Health remains a significant drag, plunging 15% as the fallout from the Q2 2025 order management disruption lingers. The most alarming break in trend is profitability: Adjusted EBITDA reversed sharply to negative $4.5M. To hit its reaffirmed FY26 EBITDA guidance of $37-$49M, Myriad will need an aggressive acceleration in the remaining three quarters.
🐂 Bull Case
GeneSight revenue jumped 24% on just 7% volume growth. This outsized revenue acceleration proves that Myriad has successfully navigated past the UnitedHealthcare coverage loss from 2025 and is reclaiming pricing power.
Cancer Care Continuum test volume grew a healthy 13%. This growing installed base of oncologists is critical for the cross-selling phase of the newly launched Precise MRD product.
🐻 Bear Case
Prenatal volumes collapsed 12% YoY. What was previously framed as a temporary operational friction (order management system) is resulting in sustained market share loss.
Adjusted EBITDA reversed to negative $4.5M. Operating expenses grew $5.1M YoY to support commercial expansion, creating a fixed-cost burden that the current 2% revenue growth cannot cover.
⚖️ Verdict: 🔴
Cautious. While the GeneSight turnaround is highly encouraging, the lingering structural damage to the Prenatal segment and the sudden dive into negative EBITDA create massive execution risk to achieve the reaffirmed full-year targets.
Key Themes
Mental Health Reimbursement Recovery
The Mental Health segment is Accelerating rapidly. Revenue jumped 24% YoY to $38.3M, vastly outpacing the 7% volume growth. This indicates significantly improved reimbursement trends and proves the company has successfully lapped the UnitedHealthcare coverage headwind that devastated this segment in early 2025.
Precise MRD Alpha Launch
Myriad successfully initiated the limited launch of its Precise Molecular Residual Disease (MRD) assay for breast cancer. Data presented at AACR and SGO demonstrated its ultrasensitive detection capabilities. While management previously noted this won't drive material 2026 revenue, it firmly establishes Myriad's foothold in the high-growth, recurring-revenue monitoring market.
Cancer Care Installed Base Growth
Cancer Care Continuum test volumes grew 13% YoY to 96,000 tests. The Japanese MHLW approval of MyChoice CDx for prostate cancer (Lynparza) further expands the total addressable market. Building this volume base is the core prerequisite for the company's broader oncology cross-selling strategy.
Prenatal Disruption Lingers
The Prenatal Health segment is Decelerating and remains the primary laggard. Revenue dropped 15% and volume fell 12% YoY. Management admits this is a difficult comparison, but it clearly illustrates that the 'self-induced' order management system disruption from Q2 2025 has caused lasting damage to customer relationships and market share.
Operating Leverage Reverses
Profitability is Reversing. Adjusted EBITDA went from $14.3M in 25Q4 to negative $4.5M in 26Q1. Adjusted operating expenses increased by $7.9M YoY to $148.5M, driven by management's multi-year commercial investment program. If revenue growth doesn't drastically accelerate to absorb these fixed costs, the FY26 profit targets are mathematically out of reach.
Pricing Pressure in Cancer Care
A specific contradiction exists in the oncology narrative: Cancer Care volume grew an impressive 13%, but segment revenue grew only 4%. This 900 basis-point gap highlights ongoing negative pricing pressure or unfavorable test mix shifts that are dampening the financial impact of the volume gains.
Segment Divergence Visualized
The Q1 results highlight a company moving in three different directions simultaneously. Mental health is capturing price, oncology is capturing volume but sacrificing price, and prenatal is losing both.
Other KPIs
Reversing from positive $11.9M last quarter. The burn was driven by a $13.4M adjusted operating cash outflow and $6.5M in capital expenditures. Cash and equivalents dwindled to $124.4M from $149.6M at the end of FY25, reducing the buffer for execution missteps as the company ramps up new product launches.
Stable. Up slightly by 20 basis points from 26Q1's 68.6% (calculated from gross profit), showing that laboratory efficiencies and the Mental Health pricing recovery are successfully offsetting the pricing headwinds in the Cancer Care segment.
Guidance
Reaffirmed. At the midpoint ($870M), this implies a 5.5% YoY growth over FY25's $824.5M. Since Q1 delivered only 2% growth, management is implicitly banking on Accelerating performance, stating they expect H2 2026 revenue to be greater than H1.
Reaffirmed. This target demands massive Acceleration. With Q1 printing a $4.5M loss, the company must generate an average of $15.8M in Adjusted EBITDA per quarter for the rest of the year just to hit the midpoint. This leaves zero room for error and heavily relies on the promised H2 revenue ramp.
Key Questions
Bridge to EBITDA Guidance
With Q1 Adjusted EBITDA at negative $4.5M, you need to average nearly $16M per quarter for the rest of the year to hit the midpoint of guidance. What specific sequential cost reductions or revenue inflection points provide visibility into this massive acceleration?
Prenatal Account Recovery
Prenatal volumes fell 12% YoY, indicating that the Q2 2025 order management disruption had a structural impact. How many active high-volume accounts were permanently lost to competitors, and what is the specific timeline for the 'rebuild phase' to yield positive volume growth?
Cancer Care Pricing Gap
Cancer Care volume grew 13% but revenue only grew 4%. What is driving this 900 basis-point gap, and should we expect this level of ASP compression to continue throughout 2026?